On January 1^st, 2018 the RECOMB project has started. The aim of the project is to fill the unmet medical need for the most common major category of SCID, recombination activating gene-1 (RAG-1) deficient SCID, by performing Stage I/II clinical trials using autologous hematopoietic stem cell basedgene therapy. The RECOMB consortium, with 17 partner institutes, brings together a large number of clinical and research experts in the field of management of a lethal orphan disease, i.e., SCID to provide solutionfor the treatment of SCID patients. Read more about our project and consortium.